B-UVB phototherapy versus Excimer laser after mini-grafting in vitiligo patients

Academic Medical Center (AMC) (The Netherlands)0 个研究点目标入组 14 人开始时间: 2007年1月16日最近更新: 2021年1月25日

适应症

试验速览

•1. Consecutive patients, diagnosed with stable vitiligo vulgaris (a few to many widespread depigmented macules over the entire body, with often a symmetrically distribution pattern) with symmetrical vitiligo patches. Definition of stable: no expansion of existing lesions or appearance of new lesions during the previous six months, absence of Koebner's phenomenon and a positive mini-grafting test
•2. Patients, eligible for mini-grafting and NB-UVB/excimer therapy
•3. Adult patients: older than 18 years

•1. With a history of hypertrophic scarring and/or keloid
•2. With a history of allergic/phototoxic reaction (Lidocaine, Tegaderm, Suture strips, sunlight)
•3. With a negative mini-grafting test
•4. With a personal or a family history of skin cancer (non-melanoma skin cancer: first degree family members, melanoma: any family member)
•5. With a personal history of photosensitivity and/or phototoxicity disorders
•6. With skin type I (according to Fitzpatrick classification I-VI)
•7. Who are pregnant
•8. Who are taking medications known to cause photosensitivity and/or phototoxicity and chronic or very frequent use of any medication that can influence the UVB response (e.g. tetracycline, retinoids, sulfonamids, psoralens, Non-Steroidal Anti-Inflammatory Drugs [NSAIDs])
•9. With other skin diseases that would impair evaluation of repigmentation, such as psoriasis and eczema
•10. Who are not able to have two times weekly NB-UVB/Excimer therapy
•11. With local immunosuppressive treatment six weeks prior to enrolment. For these patients a washout period of six weeks will be required

发起方

Academic Medical Center (AMC) (The Netherlands)